Due to an equipment failure the availability of albumin is currently limited
Biotest has started to inform its customers about an expected albumin supply shortage within the coming months. This is due to an equipment failure in the production of an albumin intermediate. The equipment failure has already been fixed.
In accordance with the relevant authorities, Biotest decided that all batches which have been produced in the affected equipment and have already been supplied, must not be used until the issue is clarified.
Additional necessary analyses are currently conducted. The company expect results within the next four weeks. Biotest will take further steps on the basis of these analysis data. The impact on sales and annual results for the Biotest Group are only assessable afterwards.
Other news from the department manufacturing

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
Last viewed contents
Global Bioenergies announces break-through in direct biological production of butadiene
Scil Technology Acquires Rights to Worldwide Patents for CD-RAP from Roche Diagnostics GmbH
Global Bioenergies adapts its Bio-Isobutene process to sucrose

Photopharmacology: using light to control cold sensors - Researchers have developed a molecule that allows an important ion channel to be regulated – a breakthrough with therapeutic potential
No new neurons in the human olfactory bulb

Study finds mushroom enzyme effective in combating hepatitis C - White mushroom enzyme has antiviral action against the hepatitis C virus and inhibits its multiplication

Zoom in to watch DNA code being read
Host genome controls skin microbiota and inflammation
Revotar announces promising results suggesting COPD as a potential target for selectin antagonist treatment in humans

Merck Discontinues Development of SARS-CoV-2/COVID-19 Vaccine Candidates - Company continues Development of Two Investigational Therapeutic Candidates

Half a needle in a haystack - New method rapidly detects trace amounts of small molecule compounds
